Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.43 |
| ▸ | CTSD | P07339 | 1/20 | 0.43 |
| ▸ | GLS | O94925 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | FEN1 | P39748 | 2/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 2/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.40 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17075684 | 1.00 | BACE1 (0.43) | BACE1CTSDGLSCYP2C9FEN1 | |
| SCHEMBL17075574 | 0.83 | MET (0.59) | METIRAK1 | |
| SCHEMBL17075572 | 0.83 | MET (0.59) | METIRAK1 | |
| SCHEMBL17075580 | 0.82 | EPHA2 (0.41) | MET | |
| SCHEMBL17075578 | 0.82 | EPHA2 (0.41) | MET | |
| SCHEMBL30922638 | 0.76 | FEN1 (0.46) | BACE1CTSDGLSCYP2C9FEN1 | |
| SCHEMBL3461642 | 0.75 | BACE1 (0.48) | BACE1CTSDGLSCYP2C9FEN1 | |
| SCHEMBL2802074 | 0.75 | FEN1 (0.45) | BACE1CTSDGLSCYP2C9FEN1 | |
| SCHEMBL17075714 | 0.74 | IRAK1 (0.53) | BACE1CTSDGLSCYP2C9FEN1 | |
| SCHEMBL482351 | 0.74 | IRAK1 (0.53) | BACE1CTSDGLSCYP2C9FEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3053923-B1 | TRIAZOLOPYRAZINE DERIVATIVES AS TYROSIN KINASE INHIBITORS | KOREA RES INST CHEMICAL TECH (KR) | 2018-04-11 | — | — | EP | disclosed |
| EP-3053923-A1 | NOVEL TRIAZOLOPYRAZINE DERIVATIVE AND USE THEREOF | Korea Research Institute of Chemical Technology (KR) | 2016-08-10 | — | — | EP | disclosed |
| US-9403831-B2 | Triazolopyrazine derivative and use thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2016-08-02 | — | — | US | disclosed |
| US-9403831-B2 | Triazolopyrazine derivative and use thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2016-08-02 | — | — | US | disclosed |
| US-9403831-B2 | Triazolopyrazine derivative and use thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2016-08-02 | — | — | US | disclosed |
| US-20150259350-A1 | NOVEL TRIAZOLOPYRAZINE DERIVATIVE AND USE THEREOF | HANDOK INC. (KR) | 2015-09-17 | — | — | US | disclosed |
| US-20150259350-A1 | NOVEL TRIAZOLOPYRAZINE DERIVATIVE AND USE THEREOF | HANDOK INC. (KR) | 2015-09-17 | — | — | US | disclosed |
| US-20150259350-A1 | NOVEL TRIAZOLOPYRAZINE DERIVATIVE AND USE THEREOF | HANDOK INC. (KR) | 2015-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259350-A1 | NOVEL TRIAZOLOPYRAZINE DERIVATIVE AND USE THEREOF | MET, RET, BRAF | BACE1 3480/4885CTSD 1977/4885GLS 1544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.